JPWO2021089850A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021089850A5
JPWO2021089850A5 JP2022525998A JP2022525998A JPWO2021089850A5 JP WO2021089850 A5 JPWO2021089850 A5 JP WO2021089850A5 JP 2022525998 A JP2022525998 A JP 2022525998A JP 2022525998 A JP2022525998 A JP 2022525998A JP WO2021089850 A5 JPWO2021089850 A5 JP WO2021089850A5
Authority
JP
Japan
Prior art keywords
antibody
region
molar ratio
antigen
substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022525998A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500701A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/081389 external-priority patent/WO2021089850A1/fr
Publication of JP2023500701A publication Critical patent/JP2023500701A/ja
Publication of JPWO2021089850A5 publication Critical patent/JPWO2021089850A5/ja
Pending legal-status Critical Current

Links

JP2022525998A 2019-11-06 2020-11-06 抗体変種の組み合わせおよびその使用 Pending JP2023500701A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201901296 2019-11-06
DKPA201901296 2019-11-06
PCT/EP2020/081389 WO2021089850A1 (fr) 2019-11-06 2020-11-06 Combinaisons de variants d'anticorps et leurs utilisations

Publications (2)

Publication Number Publication Date
JP2023500701A JP2023500701A (ja) 2023-01-10
JPWO2021089850A5 true JPWO2021089850A5 (fr) 2023-11-10

Family

ID=73449012

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022525998A Pending JP2023500701A (ja) 2019-11-06 2020-11-06 抗体変種の組み合わせおよびその使用

Country Status (4)

Country Link
US (1) US20220411529A1 (fr)
EP (1) EP4055046A1 (fr)
JP (1) JP2023500701A (fr)
WO (1) WO2021089850A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021510740A (ja) * 2018-01-24 2021-04-30 ゲンマブ ビー.ブイ. ポリペプチド変種およびそれらの用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69830901T2 (de) 1997-05-02 2006-05-24 Genentech Inc., San Francisco ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
PT2314629E (pt) 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
EP3284753B1 (fr) 2002-10-17 2019-06-05 Genmab A/S Anticorps monoclonaux humains contre le cd20 pour le traitement de la sclérose en plaques
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
EP3623473A1 (fr) 2005-03-31 2020-03-18 Chugai Seiyaku Kabushiki Kaisha Procédé pour la production de polypeptide au moyen de la régulation d'un ensemble
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR20080090406A (ko) 2005-11-28 2008-10-08 젠맵 에이/에스 재조합 1가 항체 및 그의 제조 방법
NZ591252A (en) 2006-03-17 2012-06-29 Biogen Idec Inc Methods of designing antibody or antigen binding fragments thereof with substituted non-covarying amino acids
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
PL2158221T3 (pl) 2007-06-21 2019-02-28 Macrogenics, Inc. Kowalencyjne diaciała i ich zastosowania
DK2235064T3 (en) 2008-01-07 2016-01-11 Amgen Inc A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
JP5397668B2 (ja) 2008-09-02 2014-01-22 ソニー株式会社 記憶素子および記憶装置
AU2009335798B2 (en) 2008-12-19 2014-11-27 Macrogenics, Inc. Covalent diabodies and uses thereof
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
EP2445936A1 (fr) 2009-06-26 2012-05-02 Regeneron Pharmaceuticals, Inc. Anticorps bispécifiques facilement isolés avec un format d'immunoglobuline native
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
BR112012012983A2 (pt) 2009-12-04 2020-09-15 Genentech Inc método para sintetizar um anticorpo multiespecífico, método para sintetizar um painel de anticorpos multiespecíficos, método para sintetizar um análogo de anticorpo, método para sintetizar um painel de análogos de anticorpo e composições
AR080513A1 (es) 2010-03-12 2012-04-11 Inmunogen Inc Moleculas de union cd37 y sus inmunoconjugados
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗-vegf/抗-ang-2抗體
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
EP2569337A1 (fr) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Protéines hétérodimériques et leurs procédés de production et de purification
NO2582728T3 (fr) 2010-06-15 2018-01-20
PT2606064E (pt) 2010-08-16 2015-06-08 Novimmune Sa Processos para a geração de anticorpos poliespecíficos e polivalentes
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
KR101612999B1 (ko) 2010-08-24 2016-04-15 로슈 글리카트 아게 활성화가능 이중특이적 항체
RS59589B1 (sr) 2010-11-05 2019-12-31 Zymeworks Inc Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu
KR20160044598A (ko) 2011-03-29 2016-04-25 로슈 글리카트 아게 항체 Fc 변이체
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
DK2794905T3 (da) 2011-12-20 2020-07-06 Medimmune Llc Modificerede polypeptider til bispecifikke antistofgrundstrukturer
NZ772318A (en) 2012-04-20 2023-06-30 Merus Nv Methods and means for the production of ig-like molecules
CN104736174B (zh) * 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
EP2684896A1 (fr) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anticorps de la famille anti-DR5 ou bispécifique anticorps de la famille anti-DR5 multivalents et leurs procédés d'utilisation
MX2015002269A (es) 2012-08-20 2015-07-06 Gliknik Inc Moleculas con actividad de union al antigeno y al receptor fc gamma polivalente.
KR20160007478A (ko) 2013-01-10 2016-01-20 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
US20170029505A1 (en) 2014-04-16 2017-02-02 Ucb Biopharma Sprl Multimeric fc proteins
MA43365A (fr) 2015-12-01 2018-10-10 Genmab Bv Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
CA3033661A1 (fr) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Conception d'anticorps modifies et d'autres molecules contenant un domaine fc presentant des fonctions d'agonisme et d'effecteur ameliorees
JP2021510740A (ja) 2018-01-24 2021-04-30 ゲンマブ ビー.ブイ. ポリペプチド変種およびそれらの用途

Similar Documents

Publication Publication Date Title
US20220025047A1 (en) Cd3 binding antibodies
US20230082273A1 (en) Bispecific recombinant protein and use thereof
AU2017281034B2 (en) CD3 binding antibodies
JP4494977B2 (ja) Gd2に結合するマウス14.18抗体のヒト化抗体(h14.18)およびそのil−2融合タンパク質
US20210371538A1 (en) Bispecific antibodies against cd3 and cd20
CN110891971A (zh) 仅有重链的抗bcma抗体
CN104363919A (zh) 具有改进的体内稳定性、药物代谢动力学和功效的多聚体复合物
JP2021534735A (ja) ヒトTim−3に対するモノクローナル抗体
KR20180132731A (ko) 재조합 정맥내 면역글로불린(rIVIG) 조성물 및 이의 제조 및 사용 방법
WO2018102304A1 (fr) Méthodes de traitement du cancer du sein positif à prlr
CA3062479A1 (fr) Proteine recombinante bispecifique et son utilisation
JPWO2021089850A5 (fr)
CN112672759B (zh) 抗程序性死亡配体-1(pd-l1)抗体的抗肿瘤用途
EP4248995A1 (fr) Utilisation d'anticorps anti-ox40 pour le traitement de tumeurs ou de cancers
WO2024124107A2 (fr) Agent bloquant cd47 et polythérapie anticorps bispécifiques anti-cd20/anti-cd3
RU2807216C2 (ru) Антитела, связывающие cd3
Oostindie Clustering: a rational design principle for potentiated antibod therapeutics
JPWO2019211472A5 (fr)
CN115279791A (zh) 靶向her2的抗原结合构建体及用途
NZ785574A (en) CD3 binding antibodies